Skip to main content

Kevin D. Accola, MD

Kevin D. Accola, MD

Cardiovascular and Thoracic Surgeon

, , , , , , , , , , , , , , , Cardiovascular, ,

Kevin Accola

Overview

Dr. Kevin D. Accola, MD is a board-certified internal medicine, hematology and oncology physician. Dr. Accola earned his medical degree from the University of Illinois at Chicago and completed his internship and medical residency at Baylor College of Medicine & Emory University School of Medicine. To date, he has performed approximately 9,000 cardiac surgical procedures, of which 2,400 (currently 300+ cases per year) involved heart valve operations. As an established member of the surgical community, Dr. Accola is a member of many medical organizations, including but not limited to, the Patient Advocacy Council, the Society of Thoracic Surgeons, the Florida Medical Association, the Florida Society of Thoracic Cardiovascular Surgeons Council,and the American College of Cardiology. Dr. Accola's cardiac specialties include mitral valve repair, aortic valve procedures, and ascending aortic aneurysm. His clinical interests comprise new valvular technology, cardiac protective drugs, and critical care studies.

Articles

Low-Dose Versus Standard Warfarin After Mechanical Mitral Valve Replacement: A Randomized Controlled Trial.

The Annals of thoracic surgery

2022

Commentary: Identifying patients who do not improve following surgical ventricular reduction: Is diastolic dysfunction the culprit?

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

2021

Commentary: Anticoagulation strategies: Awaiting a new paradigm.

The Journal of thoracic and cardiovascular surgery

2021

Commentary: Valve options for ischemic mitral regurgitation in an era of new technologies: ViV(a) la bioprosthetic.

The Journal of thoracic and cardiovascular surgery

2021

Reflections on 40 Years of Workforce Surveys: How the Times Have Changed

ANNALS OF THORACIC SURGERY

2020

Commentary: Business as usual: A thing of the past

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

2020

Reflections on a Career in Cardiothoracic Surgery: Maintaining Humanism in a Changing Environment

ANNALS OF THORACIC SURGERY

2020

Best Practices of Aortic Valve Replacement With the Edwards Intuity Elite Valve

ANNALS OF THORACIC SURGERY

2020

A Man in His Early 70s With Aortic Stenosis and Discoloration of the Aortic Valve

JAMA CARDIOLOGY

2019

Commentary: Functional or secondary mitral valve regurgitation: Pathoanatomy versus etiology... changing paradigms and treatment strategies

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

2019

Education & Training

Education

Rush Medical College

Residency

Baylor College Of Medicine; Emory University

Fellowship

Emory University Hospital

Specialty

Thoracic & Cardiovascular Surgery

Board Certifications

American Board of Thoracic Surgery

Associated Clinical Trials

NCT03706833

CLASP IID/IIF - A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Mitral Valve Repair System compared to Abbott Mitraclip in patients with degenerative mitral regurgitation.

Icon for trial | 2018-07 CLASP IID/IIF - A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Mitral Valve Repair System compared to Abbott Mitr

This study is currently enrolling.

The goal of this study is to assess the safety and performance of the PASCAL System in patients with symptomatic degenerative mitral regurgitation (DMR). Up to 300 participants will take part in this randomized study at up to 7 ...

NCT04142658

PROACT Xa - A prospective, randomized, active (warfarin) controlled, parallel-arm clinical trial to determine if patients with an On-X aortic valve can be maintained safely and effectively on the factor Xa inhibitor apixaban

Icon for trial | ONX1801.000-C PROACT Xa - A prospective, randomized, active (warfarin) controlled, parallel-arm clinical trial to determine if patients with an On-X aortic valve can be maintained safely and effectively on the factor Xa inhibitor apixaban

This study is currently enrolling.

You are being asked to take part in this research study because you are at least 18 years old, have had an On-X mechanical valve implanted in the aortic position at least 3 months (90 days) ago, are currently receiving warfarin ...

NCT05093504

START-D - Safe and Timely Antithrombotic Removal – Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D): A Prospective, Multicenter, Double-blind, Randomized, Study DrugSorb-ATR Removal of Apixaban and Rivaroxaban to Reduce Likelihood of Serious Bleeding in Patients Undergoing Urgent Cardiothoracic Surgery

Icon for trial | 2021-02 START-D - Safe and Timely Antithrombotic Removal – Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D): A Prospective, Multicenter, Double-blind, Randomized, Study DrugSorb-ATR Removal of Apixaban and Rivaroxaban to Reduce Likelih

This study is currently enrolling.

The purpose of this study is to evaluate a new method for removing drugs like apixaban and rivaroxaban from the blood during heart or aortic surgery, using an adsorption (“sticky”) device called DrugSorb-ATR. The DrugSorb-ATR d ...

NCT04976530

START-Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T): Prospective, Multi center, Double-blind, Randomized, Study to Evaluate Reduction in Postoperative Bleeding by Removal of Ticagrelor with the Intraoperative use of the DrugSorb-ATR Device in Patients Undergoing on-pump Cardiothoracic Surgery within Two Days of Ticagrelor Discontinuation

Icon for trial | 2021-01 START-Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T): Prospective, Multi center, Double-blind, Randomized, Study to Evaluate Reduction in Postoperative Bleeding by Removal of Ticagrelor with the Intraoperative use of the DrugSorb-ATR

This study is currently enrolling.

This study is being conducted to assess the potential ability of a new method for removing drugs like ticagrelor from blood during heart or aortic surgery, using an adsorption (“sticky”) device called DrugSorb-ATR. Ticagrelor i ...